Scott J Sherman

Neurology

Phone(520) 626-2319
Emailssherman@email.arizona.edu

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Scott J Sherman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

8 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

2 Finished

Selective modulation of basal ganglia circuits
Sherman, S. J.
National Institutes of Health
3/15/02 → 2/29/04
Project: Research project
MODULATION OF K+ CHANNEL PROPERTIES BY ANTISENSE DNA
Sherman, S. J.
National Institutes of Health
9/30/97 → 7/31/03
Project: Research project

4174 Citations
30 h-Index
64 Article
3 Review article
1 Chapter
1 Conference contribution

Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine
Ye, T., Bartlett, M. J., Sherman, S. J., Falk, T. & Cowen, S. L., Jun 2021, In: Experimental Neurology. 340, 113670.
Research output: Contribution to journal › Article › peer-review
The delta-specific opioid glycopeptide bbi-11008: Cns penetration and behavioral analysis in a preclinical model of levodopa-induced dyskinesia
Bartlett, M. J., Mabrouk, O. S., Szabò, L., Flores, A. J., Parent, K. L., Bidlack, J. M., Heien, M. L., Kennedy, R. T., Polt, R., Sherman, S. J. & Falk, T., Jan 1 2021, In: International journal of molecular sciences. 22, 1, p. 1-15 15 p., 20.
Research output: Contribution to journal › Article › peer-review

Open Access
Accuracy of dopamine transporter imaging with ¹²³I-ioflupane in hispanic and non-hispanic patients
Lundeen, T. F., Covington, M., Krupinski, E. A., Avery, R., Lei, H., Sherman, S. J. & Kuo, P. H., Jun 1 2020, In: Journal of nuclear medicine technology. 48, 2, p. 154-157 4 p.
Research output: Contribution to journal › Article › peer-review
Highly-selective μ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model
Bartlett, M. J., So, L. Y., Szabò, L., Skinner, D. P., Parent, K. L., Heien, M. L., Vanderah, T. W., Polt, R., Sherman, S. J. & Falk, T., Mar 12 2020, In: BMC research notes. 13, 1, 149.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia
Bartlett, M. J., Flores, A. J., Ye, T., Smidt, S. I., Dollish, H. K., Stancati, J. A., Farrell, D. C., Parent, K. L., Doyle, K. P., Besselsen, D. G., Heien, M. L., Cowen, S. L., Steece-Collier, K., Sherman, S. J. & Falk, T., Nov 2020, In: Experimental Neurology. 333, 113413.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations

Selective modulation of basal ganglia circuits

MODULATION OF K+ CHANNEL PROPERTIES BY ANTISENSE DNA

Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine

The delta-specific opioid glycopeptide bbi-11008: Cns penetration and behavioral analysis in a preclinical model of levodopa-induced dyskinesia

Accuracy of dopamine transporter imaging with 123I-ioflupane in hispanic and non-hispanic patients

Highly-selective μ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model

Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia

Accuracy of dopamine transporter imaging with ¹²³I-ioflupane in hispanic and non-hispanic patients